Rezzayo
Payments companies reported to CMS as associated with Rezzayo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rezzayo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rezzayo
These are the largest totals companies reported as associated with Rezzayo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jose Vazquez | Augusta, GA | Infectious Disease | $134,765.03 |
| Amar Safdar | Houston, TX | Infectious Disease | $114,054.50 |
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $73,538.09 |
| Hector Brunet Rodriguez | Shreveport, LA | Infectious Disease | $44,031.42 |
| Casmiar Nwaigwe | Minot, ND | Infectious Disease | $27,141.91 |
| Ali Hassoun | Huntsville, AL | Infectious Disease | $18,676.81 |
| Brandon Smith | Pittsburgh, PA | Infectious Disease | $15,496.64 |
| George Sakoulas | San Diego, CA | Infectious Disease | $12,955.47 |
| Stephen Weinroth | Fairfax, VA | Infectious Disease | $12,108.76 |
| Fares Khater | Whitesburg, KY | Internal Medicine | $11,310.94 |
Prescribed Rezzayo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.